Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

Mult Scler. 2023 Feb;29(2):236-247. doi: 10.1177/13524585221139156. Epub 2022 Dec 14.

Abstract

Background: In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression.

Objective: We aimed to develop and validate a dynamic score to guide the early decision to switch from first- to second-line therapy.

Methods: Using time-dependent propensity scores (PS) from a French cohort of 12,823 patients with RRMS, we constructed one training and two validation PS-matched cohorts to compare the switched patients to second-line treatment and the maintained patients. We used a frailty Cox model for predicting individual hazard ratios (iHRs).

Results: From the validation PS-matched cohort of 348 independent patients with iHR ⩽ 0.69, we reported the 5-year relapse-free survival at 0.14 (95% confidence interval (CI) 0.09-0.22) for the waiting group and 0.40 (95% CI 0.32-0.51) for the switched group. From the validation PS-matched cohort of 518 independent patients with iHR > 0.69, these values were 0.37 (95% CI 0.30-0.46) and 0.44 (95% CI 0.37-0.52), respectively.

Conclusions: By using the proposed dynamic score, we estimated that at least one-third of patients could benefit from an earlier switch to prevent relapse.

Keywords: Epidemiology; multiple sclerosis; second-line treatment; treatment response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunologic Factors
  • Multiple Sclerosis*
  • Multiple Sclerosis, Relapsing-Remitting* / drug therapy

Substances

  • Immunologic Factors